Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human ARL2BP Antibodies:
anti-Mouse (Murine) ARL2BP Antibodies:
anti-Rat (Rattus) ARL2BP Antibodies:
Go to our pre-filtered search.
This study identified two homozygous variants in ARL2BP as a rare cause of autosomal recessive retinitis pigmentosa. Further studies are required to define the underlying disease mechanism causing retinal degeneration as a result of mutations in ARL2BP and any phenotype-genotype correlation associated with residual levels of the wild-type transcript.
Subsequent analysis of 844 index cases did not reveal further pathogenic chances in ARL2BP indicating that mutations in ARL2B are a rare cause of arRCD (about 0.1%) in a large cohort of French patients.
Alteration of EBV encoded miR-BART1 expression results in an increase in migration and invasion of nasopharyngeal carcinoma in vitro and causes metastasis in vivo. EBV-miR-BART1 directly targets the cellular tumour suppressor PTEN.
EBV also downregulates two immediate early (show JUN Antibodies) genes by miR (show MLXIP Antibodies)-BART20-5p.
Mutations in ARL2BP cause autosomal-recessive retinitis pigmentosa.
EBV-miR (show MLXIP Antibodies)-BART1 could influence the expression of metabolism-associated genes and might be involved in cancer metabolism in nasopharyngeal carcinoma
Our results imply that BART (show BSND Antibodies) regulates actin-cytoskeleton rearrangements at membrane ruffles through modulation of the activity of Rac1 (show RAC1 Antibodies), which, in turn, inhibits pancreatic cancer cell invasion.
These results imply that BART (show BSND Antibodies) contributes to regulating PKCalpha (show PKCa Antibodies) activity through binding to ANX7 (show ANXA7 Antibodies), thereby affecting the invasiveness of pancreatic cancer cells.
We identify a subset of BART (show BSND Antibodies) miRNAs that are restricted to Latency III in normal infection but are up regulated in tumors that express Latency I and II.
Our results imply that BART (show BSND Antibodies) increases active RhoA (show RHOA Antibodies) by inhibiting ARL2 (show ARL2 Antibodies) function, which in turn inhibits invasiveness of cancer cells.
BART is essential for the transcriptional activity and nuclear retention of STAT3 (show STAT3 Antibodies)
ADP-ribosylation factor (ARF)-like proteins (ARLs) comprise a functionally distinct group of the ARF family of RAS-related GTPases. The protein encoded by this gene binds to ARL2.GTP with high affinity but does not interact with ARL2.GDP, activated ARF, or RHO proteins. The lack of detectable membrane association of this protein or ARL2 upon activation of ARL2 is suggestive of actions distinct from those of the ARFs. This protein is considered to be the first ARL2-specific effector identified, due to its interaction with ARL2.GTP but lack of ARL2 GTPase-activating protein activity.
ADP-ribosylation factor-like protein 2-binding protein
, ARF-like 2-binding protein
, ADP-ribosylation factor-like 2 binding protein
, Arf-like 2 binding protein BART1
, binder of ARF2 protein 1
, binder of Arl Two
, binder of Arl2
, ADP-ribosylation-like 2 binding protein